eISSN: 1897-4309
ISSN: 1428-2526
Contemporary Oncology/Współczesna Onkologia
Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
2/2024
vol. 28
 
Share:
Send email
Share:
Original paper

Evaluation of outcome and safety profile in high-dose BEAM and Benda-EAM chemotherapy with subsequent autologous stem cell transplantation in lymphoma patients

Kinga Krawiec
1
,
Piotr Strzałka
1
,
Olga Racińska
2
,
Marcin Kędzior
2
,
Hubert Sowul
2
,
Wojciech Salamon
2
,
Kacper Kościelny
2
,
Michał Kośny
1
,
Damian Mikulski
3
,
Agnieszka Pluta
1
,
Agnieszka Wierzbowska
1

  1. Department of Hematology, Medical University of Łódź, Łódź, Poland
  2. Medical University of Łódź, Łódź, Poland
  3. Department of Biostatistics and Translational Medicine, Medical University of Łódź, Łódź, Poland
Contemp Oncol (Pozn) 2024; 28 (2): 158–166
DOI: https://doi.org/10.5114/wo.2024.141794
Online publish date: 2024/07/26
Article file
- Evaluation of outcome (1).pdf  [0.12 MB]
Get citation
 
PlumX metrics:
 
1. Styczyński J, Tridello G, Koster L, et al. Infectious diseases working party EBMT. Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factors. Bone Marrow Transplant 2020; 55: 126-136.
2. Passweg JR, Baldomero H, Ciceri F, et al. Hematopoietic cell transplantation and cellular therapies in Europe 2021. The second year of the SARS-CoV-2 pandemic. A Report from the EBMT Activity Survey. Bone Marrow Transplant 2023; 6: 1-12.
3. Fujimoto A, Anzai T, Fukuda T, et al. Impact of event-free survival status after stem cell transplantation on subsequent survival of patients with lymphoma. Blood Adv 2021; 5: 1412-1424.
4. Mina AA, Vakkalagadda C, Pro B. Novel therapies and approaches to relapsed/refractory HL beyond chemotherapy. Cancers (Basel) 2019; 11: 421.
5. Elis A, Blickstein D, Klein O, Eliav-Ronen R, Manor Y, Lishner M. Detection of relapse in non-Hodgkin’s lymphoma: role of routine follow-up studies. Am J Hematol 2002; 69: 41-44.
6. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med 1995; 333: 1540-1545.
7. Krawiec K, Czemerska M, Stelmach P, et al. Assessment of colonization and infection epidemiology in patients undergoing autologous hematopoietic stem cell transplantation: a single-center study. Acta Haematol Pol 2022; 53: 133-140.
8. Lachance S, Bourguignon A, Boisjoly JA, et al. Impact of implementing a bendamustine-based conditioning regimen on outcomes of autologous stem cell transplantation in lymphoma while novel cellular therapies emerge. Transplant Cell Ther 2023; 29: 34.e1-34.e7.
9. Samara Y, Mei M. Autologous stem cell transplantation in Hodgkin lymphoma-latest advances in the era of novel therapies. Cancers (Basel) 2022; 14: 1738.
10. Hueso T, Gastinne T, Garciaz S, et al. Bendamustine-EAM versus BEAM regimen in patients with mantle cell lymphoma undergoing autologous stem cell transplantation in the frontline setting: a multicenter retrospective study from Lymphoma Study Association (LYSA) centers. Bone Marrow Transplant 2020; 55: 1076-1084.
11. AlJohani NI, Nasani M, Ahmed HE, et al. Dose-adjusted bendamustine as a replacement for carmustine in autologous stem cell transplant conditioning for patients with relapsed lymphoma: a retrospective single-center study. Hematol Oncol Stem Cell Ther 2021; 14: 327-335.
12. Hahn L, Lim H, Dusyk T, et al. BeEAM conditioning regimen is a safe, efficacious and economical alternative to BEAM chemotherapy. Sci Rep 2021; 11: 14071.
13. Chantepie S, Tchernonog E, Peyrade F, et al. Bendamustine-based (BeEAM) conditioning before autologous stem cell transplantation: result of a French multicenter study of 386 patients from Lysa Centers. Blood 2016; 128: 3450.
14. Gilli S, Novak U, Taleghani BM, et al. BeEAM conditioning with bendamustine-replacing BCNU before autologous transplantation is safe and effective in lymphoma patients. Ann Hematol 2017; 96: 421-429.
15. Averbuch D, Orasch C, Cordonnier C, et al. ECIL4, a joint venture of EBMT, EORTC, ICHS, ESGICH/ESCMID and ELN. European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia. Haematologica 2013; 98: 1826-1835.
16. Frankiewicz A, Saduś-Wojciechowska M, Najda J, et al. Comparable safety profile of BeEAM (bendamustine, etoposide, cytarabine, melphalan) and BEAM (carmustine, etoposide, cytarabine, melphalan) as conditioning before autologous haematopoietic cell transplantation. Contemp Oncol (Pozn) 2018; 22: 113-117.
17. Saleh K, Danu A, Koscielny S, et al. A retrospective, matched paired analysis comparing bendamustine containing BeEAM versus BEAM conditioning regimen: results from a single center experience. Leuk Lymphoma 2018; 59: 2580-2587.
18. Tsang ES, Villa D, Loscocco F, et al. High-dose Benda-EAM versus BEAM in patients with relapsed/refractory classical Hodgkin lymphoma undergoing autologous stem cell transplantation. Bone Marrow Transplant 2019; 54: 481-484.
19. Visani G, Malerba L, Stefani PM, et al. BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients. Blood 2011; 118: 3419-3425.
20. Alessandrino EP, Bernasconi P, Colombo A, et al. Pulmonary toxicity following carmustine-based preparative regimens and autologous peripheral blood progenitor cell transplantation in hematological malignancies. Bone Marrow Transplant 2000; 25: 309-313.
21. Stuart MJ, Chao NS, Horning SJ, et al. Efficacy and toxicity of a CCNU-containing high-dose chemotherapy regimen followed by autologous hematopoietic cell transplantation in relapsed or refractory Hodgkin’s disease. Biol Blood Marrow Transplant 2001; 7: 552-560.
22. Till BG, Madtes DK. BCNU-associated pneumonitis: portrait of a toxicity. Leuk Lymphoma 2012; 53: 1019-1020.
23. Lane AA, Armand P, Feng Y, et al. Risk factors for development of pneumonitis after high-dose chemotherapy with cyclophosphamide, BCNU and etoposide followed by autologous stem cell transplant. Leuk Lymphoma 2012; 53: 1130-1136.
24. Prediletto I, Farag SA, Bacher U, et al. High incidence of reversible renal toxicity of dose-intensified bendamustine-based high-dose chemotherapy in lymphoma and myeloma patients. Bone Marrow Transplant 2019; 54: 1923-1925.
25. Garciaz S, Coso D, Schiano de Collela JM, et al. Bendamustine- based conditioning for non-Hodgkin lymphoma autologous transplantation: an increasing risk of renal toxicity. Bone Marrow Transplant 2016; 51: 319-321.
26. Gratwohl A, Brand R, Frassoni F, et al. Acute and chronic leukemia working parties, infectious diseases working party of the European Group for Blood and Marrow Transplantation. Cause of death after allogeneic haematopoietic stem cell transplantation (HSCT) in early leukaemias: an EBMT analysis of lethal infectious complications and changes over calendar time. Bone Marrow Transplant 2005; 36: 757-769.
27. Gil L, Styczynski J, Komarnicki M. Infectious complication in 314 patients after high-dose therapy and autologous hematopoietic stem cell transplantation: risk factors analysis and outcome. Infection 2007; 35: 421-427.
28. Srinivasan A, Wang C, Srivastava DK, et al. Timeline, epidemiology, and risk factors for bacterial, fungal, and viral infections in children and adolescents after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2013; 19: 94-101.
29. Sahai T, Hauser N, Mukkamalla SKR, et al. Outcomes of febrile neutropenia following hematopoietic stem cell transplantation. JCO 2016; 34: e18562-e18562.
30. Baden LR, Bensinger W, Angarone M, et al. Prevention and treatment of cancer-related infections. J Natl Compr Canc Netw 2012; 10: 1412-1445.
31. Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 2009; 15: 1143-1238. Erratum in: Biol Blood Marrow Transplant 2010; 16: 294. Boeckh, Michael A [corrected to Boeckh, Michael J].
32. Styczynski J, Czyzewski K, Wysocki M, et al. Increased risk of infections and infection-related mortality in children undergoing haematopoietic stem cell transplantation compared to conventional anticancer therapy: a multicentre nationwide study. Clin Microbiol Infect 2016; 22: 179.e1-179.e10.
33. Lindsay J, Kerridge I, Wilcox L, et al. Infection-related mortality in adults and children undergoing allogeneic hematopoietic cell transplantation: an australian registry report. Transplant Cell Ther 2021; 27: 798.e1-798.e10.
34. Bolon YT, Atshan R, Allbee-Johnson M, Estrada-Merly N, Lee SJ. Current use and outcome of hematopoietic stem cell transplantation: CIBMTR summary slides, 2022. Available from: http://www.cibmtr.org.
35. Salazar R, Solá C, Maroto P, et al. Infectious complications in 126 patients treated with high-dose chemotherapy and autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 1999; 23: 27-33.
36. Wang CH, Chang FY, Chao TY, et al. Characteristics comparisons of bacteremia in allogeneic and autologous hematopoietic stem cell-transplant recipients with levofloxacin prophylaxis and influence on resistant bacteria emergence. J Microbiol Immunol Infect 2018; 51: 123-131.
37. Signorelli J, Zimmer A, Liewer S, Shostrom VK, Freifeld A. Incidence of febrile neutropenia in autologous hematopoietic stem cell transplant (HSCT) recipients on levofloxacin prophylaxis. Transpl Infect Dis 2020; 22: e13225.
38. Lakatos B, Szabó H, Csordás K, et al. Autológőssejt-transzplantációt követő korai infekciók epidemiológiája. Egy hazai centrumban kezelt 699 beteg adatainak elemzése [Epidemiology of early infections after autologous hematopoietic stem cell transplantation. Analysis of data from 699 patients treated in a Hungarian centre]. Orv Hetil 2020 Jan;161: 103-109.
39. Uysala A, Ali Erkurtb M, Kukub I, et al. The effect of CD 34+ stem cell dose on both short-term and long-term outcomes of autologous stem cell transplantation in multiple myeloma. Ann Med Res 2023; 30: 331-336.
40. Domingo-Domènech E, Sureda A. Treatment of Hodgkin lymphoma relapsed after autologous stem cell transplantation. J Clin Med 2020; 9: 1384.
41. Czyz A, Lojko-Dankowska A, Dytfeld D, et al. Prognostic factors and long-term outcome of autologous haematopoietic stem cell transplantation following a uniform-modified BEAM-conditioning regimen for patients with refractory or relapsed Hodgkin lymphoma: a single-center experience. Med Oncol 2013; 30: 611.
42. Qian F, Fan W, Wei X, et al. Prognostic factors of lymphoma patients after autologous stem cell transplantation. Ann Transplant 2015; 20: 225-232.
43. Kadkhoda D, Nikoonezhad M, Baghestani AR, Parkhideh S, Momeni-Varposhti Z, Khadem Maboudi AA. Prognostic factors for the long-term survival after hematopoietic stem cell transplantation in patients with Hodgkin lymphoma. Asian Pac J Cancer Prev 2023; 24: 417-423.
44. Luo C, Li Q, Li X, et al. Prognostic role of serum albumin level in patients with lymphoma undergoing autologous stem cell transplantation. Ann Transplant 2021; 26: e933365.
45. Wei Y, Wei X, Huang W, et al. Albumin improves stratification in the low IPI risk patients with diffuse large B-cell lymphoma. Int J Hematol; 111: 681-685.
46. Wei X, Zheng J, Zhang Z, et al. Consecutive hypoalbuminemia predicts inferior outcome in patients with diffuse large B-Cell lymphoma. Front Oncol 2021; 10: 610681.
47. Bairey O, Shacham-Abulafia A, Shpilberg O, Gurion R. Serum albumin level at diagnosis of diffuse large B-cell lymphoma: an important simple prognostic factor. Hematol Oncol 2016; 34: 184-192.
48. Hohloch K, Ziepert M, Truemper L, et al. Low serum albumin is an independent risk factor in elderly patients with aggressive B-cell lymphoma: results from prospective trials of the German High-Grade Non-Hodgkin’s Lymphoma Study Group. EJHaem 2020; 1: 181-187.
Copyright: © 2024 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
FEATURED PRODUCTS
BOOKS
• Genetyka i leczenie chłoniaka rozlanego z dużych komórek B (DLBCL)
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.